1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 9
2.1 Ablation Equipments Overview 9
3 Products under Development 10
3.1 Ablation Equipments - Pipeline Products by Stage of Development 10
3.2 Ablation Equipments - Pipeline Products by Territory 11
3.3 Ablation Equipments - Pipeline Products by Regulatory Path 12
3.4 Ablation Equipments - Pipeline Products by Estimated Approval Date 13
3.5 Ablation Equipments - Ongoing Clinical Trials 14
4 Ablation Equipments - Pipeline Products under Development by Companies 15
4.1 Ablation Equipments Companies - Pipeline Products by Stage of Development 15
4.2 Ablation Equipments - Pipeline Products by Stage of Development 16
5 Ablation Equipments Companies and Product Overview 17
5.1 AngioDynamics Inc Company Overview 17
5.1.1 AngioDynamics Inc Pipeline Products & Ongoing Clinical Trials Overview 17
5.2 Avenda Health Inc Company Overview 32
5.2.1 Avenda Health Inc Pipeline Products & Ongoing Clinical Trials Overview 32
5.3 CPSI Biotech Company Overview 33
5.3.1 CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview 33
5.4 Creo Medical Ltd. Company Overview 35
5.4.1 Creo Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview 35
5.5 Deneb Medical SL Company Overview 36
5.5.1 Deneb Medical SL Pipeline Products & Ongoing Clinical Trials Overview 36
5.6 Fractyl Laboratories Inc Company Overview 37
5.6.1 Fractyl Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 37
5.7 Harmonic Medical Inc Company Overview 41
5.7.1 Harmonic Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 41
5.8 HistoSonics Inc Company Overview 44
5.8.1 HistoSonics Inc Pipeline Products & Ongoing Clinical Trials Overview 44
5.9 Hospital for Special Surgery Company Overview 45
5.9.1 Hospital for Special Surgery Pipeline Products & Ongoing Clinical Trials Overview 45
5.10 Imricor Medical Systems Inc Company Overview 46
5.10.1 Imricor Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 46
5.11 Innoblative Designs, Inc. Company Overview 49
5.11.1 Innoblative Designs, Inc. Pipeline Products & Ongoing Clinical Trials Overview 49
5.12 Integra LifeSciences Holdings Corp Company Overview 50
5.12.1 Integra LifeSciences Holdings Corp Pipeline Products & Ongoing Clinical Trials Overview 50
5.13 Intratherm LLC (Inactive) Company Overview 52
5.13.1 Intratherm LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 52
5.14 Massachusetts Institute of Technology Company Overview 53
5.14.1 Massachusetts Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 53
5.15 Medtronic plc Company Overview 54
5.15.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 54
5.16 Memorial Sloan Kettering Cancer Center Company Overview 56
5.16.1 Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 56
5.17 Mirabilis Medical Inc Company Overview 57
5.17.1 Mirabilis Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 57
5.18 Pulse Biosciences Inc Company Overview 60
5.18.1 Pulse Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 60
5.19 Southern Illinois University Carbondale Company Overview 61
5.19.1 Southern Illinois University Carbondale Pipeline Products & Ongoing Clinical Trials Overview 61
5.20 Thermedical Inc Company Overview 62
5.20.1 Thermedical Inc Pipeline Products & Ongoing Clinical Trials Overview 62
5.21 TransEnterix Inc Company Overview 63
5.21.1 TransEnterix Inc Pipeline Products & Ongoing Clinical Trials Overview 63
5.22 University of California San Francisco Company Overview 64
5.22.1 University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 64
5.23 University of Texas at Austin Company Overview 65
5.23.1 University of Texas at Austin Pipeline Products & Ongoing Clinical Trials Overview 65
5.24 University of Wisconsin-Stout Company Overview 66
5.24.1 University of Wisconsin-Stout Pipeline Products & Ongoing Clinical Trials Overview 66
6 Ablation Equipments- Recent Developments 67
6.1 Jul 11, 2018: AngioDynamics Reports Fiscal 2018 Fourth Quarter and Full-Year Financial Results 67
6.2 Jul 10, 2018: Stryker announces organizational changes 68
6.3 Jul 05, 2018: SonaCare reports long-term results of HIFU therapy for prostate cancer 69
6.4 Jun 23, 2018: Fractyl Announces Presentation of Key Scientific Research at ADA 2018 Indicating That Modern Diets Durably Alter Duodenal Lining, Highlighting the Intestine's Role in Type 2 Diabetes and NASH 69
6.5 Jun 14, 2018: HSS Hip and Knee Surgeon Bradford Waddell, MD, Named Chair of Young Arthroplasty Group 71
6.6 Jun 05, 2018: Medtronic Presents Strategic Growth Roadmap at 2018 Investor Day; Outlines Plan to Create Shareholder Value 71
7 Appendix 139
7.1 Methodology 139
7.2 About GlobalData 142
7.3 Contact Us 142
7.4 Disclaimer 142

1.1 List of Tables
Table 1: Ablation Equipments - Pipeline Products by Stage of Development 11
Table 2: Ablation Equipments - Pipeline Products by Territory 12
Table 3: Ablation Equipments - Pipeline Products by Regulatory Path 13
Table 4: Ablation Equipments - Pipeline Products by Estimated Approval Date 14
Table 5: Ablation Equipments - Ongoing Clinical Trials 15
Table 6: Ablation Equipments Companies - Pipeline Products by Stage of Development 16
Table 7: Ablation Equipments - Pipeline Products by Stage of Development 17
Table 8: AngioDynamics Inc Pipeline Products & Ongoing Clinical Trials Overview 18
Table 9: NanoKnife 3.0 - Product Status 18
Table 10: NanoKnife 3.0 - Product Description 19
Table 11: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Product Status 19
Table 12: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Product Description 19
Table 13: NanoKnife System - Pancreatic Cancer - Product Status 20
Table 14: NanoKnife System - Pancreatic Cancer - Product Description 20
Table 15: NanoKnife System - Prostate Cancer - Product Status 20
Table 16: NanoKnife System - Prostate Cancer - Product Description 21
Table 17: AngioDynamics Inc - Ongoing Clinical Trials Overview 22
Table 18: NanoKnife System - Prostate Cancer - Efficacy and Safety Assessment of Nanoknife (AngyoDynamics, USA) for Irreversible Electroporation (IRE) of Localized Prostate Cancer 24
Table 19: NanoKnife System - Prostate Cancer - Focal Irreversible Electroporation as Salvage Treatment in Radio-recurrent Prostate Cancer: A Prospective Multicenter Pilot Study 24
Table 20: NanoKnife System - Prostate Cancer - Irreversible Electroporation (IRE) for Unresectable Prostatic Neoplasms: Phase I and Phase II Clinical Trial 24
Table 21: NanoKnife System - Prostate Cancer - Multi-center Randomized Clinical Two Arm Intervention Study Evaluating Irreversible Electroporation for the Ablation of Localized Prostate Cancer 25
Table 22: NanoKnife System - Prostate Cancer - Registry of Irreversible Electroporation for the Ablation of Prostate Cancer with Use of Nanoknife Device; A Multi-center, International Registry to Evaluate the Treatment of Prostate Cancer in Terms of Recurrence, Functional Outcomes and Safety 25
Table 23: NanoKnife System - Pancreatic Cancer - A Clinical Research about Using Irreversible Electroporation to Treat Locally Advanced Pancreatic Cancer 26
Table 24: NanoKnife System - Pancreatic Cancer - A Pilot Study of Irreversible Electroporation for the Treatment of Upfront Resectable Pancreatic Cancer in the Head of the Pancreas 26
Table 25: NanoKnife System - Pancreatic Cancer - Assessing Optimal Treatment Settings for the Ablation of Locally Advanced Pancreatic Cancer with CT-guided Percutaneous Irreversible Electroporation (ANTILOPE): A Randomized Feasibility Study 26
Table 26: NanoKnife System - Pancreatic Cancer - Crossatlantic Randomized Controlled Trial Comparing Outcome in Survival after Systemic Plus Focal Therapy for Inoperable Pancreatic Carcinoma: Radiotherapy Versus Irreversible Electroporation: CROSSFIRE Trial 27
Table 27: NanoKnife System - Pancreatic Cancer - Evaluation of the Short and Intermediate Term Outcomes of Ablation of Locally Advanced Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System - A Prospective Study 27
Table 28: NanoKnife System - Pancreatic Cancer - Impact of Irreversible Electroporation on Quality of Life for Patients with Locally Advanced Pancreatic Cancer 27
Table 29: NanoKnife System - Pancreatic Cancer - Interest of Irreversible Electroporation in the Treatment of Pancreatic Adenocarcinoma 28
Table 30: NanoKnife System - Pancreatic Cancer - IRE: Anti-tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer 28
Table 31: NanoKnife System - Pancreatic Cancer - Irreversible Electroporation for Locally Advanced Pancreatic Ductal Adenocarcinoma (LEAP TRIAL): A Phase I/II Prospective Trial 28
Table 32: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - A Prospective Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Unresectable Hepatic Carcinoma Close to the Gallbladder 29
Table 33: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - A Prospective Clinical Trial Using Irreversible Electroporation for the Treatment of Liver Cancers 29
Table 34: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Colorectal Metastatic Liver Disease: Efficacy of Irreversible Electroporation (IRE) - A Phase II Clinical Trial: COLDFIRE-2 Study 29
Table 35: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer 30
Table 36: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Comparison Percutaneous Cryosurgery and Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome 30
Table 37: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Hepatic Carcinoma in Poor Liver Function: Safety and Efficacy of Irreversible Electroporation (IRE) 30
Table 38: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Irreversible Electroporation (IRE) for Unresectable Portal Venous Tumor Emboli: Phase I and Phase II Clinical Trial 31
Table 39: NanoKnife 3.0 - The Safety and Feasibility of Irreversible Electroporation for the Ablation of Small Renal Masses 32
Table 40: Avenda Health Inc Pipeline Products & Ongoing Clinical Trials Overview 33
Table 41: Fiber - Optic Laser - Product Status 33
Table 42: Fiber - Optic Laser - Product Description 33
Table 43: CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview 34
Table 44: Pressurized Sub-Cooled Nitrogen System - Product Status 34
Table 45: Pressurized Sub-Cooled Nitrogen System - Product Description 34
Table 46: Super-Critical Nitrogen (SCN) Cryoablation Platform - Product Status 34
Table 47: Super-Critical Nitrogen (SCN) Cryoablation Platform - Product Description 35
Table 48: Creo Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview 36
Table 49: Flexible Ablation System - Product Status 36
Table 50: Flexible Ablation System - Product Description 36
Table 51: Deneb Medical SL Pipeline Products & Ongoing Clinical Trials Overview 37
Table 52: BoneCut Collaborative Robot - Product Status 37
Table 53: BoneCut Collaborative Robot - Product Description 37
Table 54: Fractyl Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 38
Table 55: Revita DMR System - Product Status 38
Table 56: Revita DMR System - Product Description 38
Table 57: Fractyl Laboratories Inc - Ongoing Clinical Trials Overview 39
Table 58: Revita DMR System - Evaluation of Duodenal Mucosal Resurfacing (DMR) for the Treatment of Non Alcoholic Steatohepatitis (NASH), a Proof of Concept Study 40
Table 59: Revita DMR System - Evaluation of Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes 40
Table 60: Revita DMR System - Evaluation of the Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D) 40
Table 61: Revita DMR System - Multicenter Clinical Trial of Revita DMR Procedure in Patients with Diabetes 41
Table 62: Harmonic Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 42
Table 63: Symphony MRI guided High Intensity Focused Ultrasound - Leiomyomas - Product Status 42
Table 64: Symphony MRI guided High Intensity Focused Ultrasound - Leiomyomas - Product Description 42
Table 65: Harmonic Medical Inc - Ongoing Clinical Trials Overview 43
Table 66: Symphony MRI guided High Intensity Focused Ultrasound - Leiomyomas - MRI-guided High Intensity Focused Ultrasound Ablation of Leiomyomas. Single Arm, Feasibility Study Using the Symphony - MRI Guided Focused Ultrasound System for the Treatment of Leiomyomas. 44
Table 67: HistoSonics Inc Pipeline Products & Ongoing Clinical Trials Overview 45
Table 68: Vortx RX - Product Status 45
Table 69: Vortx RX - Product Description 45
Table 70: Hospital for Special Surgery Pipeline Products & Ongoing Clinical Trials Overview 46
Table 71: Radiofrequency Ablation Device - Product Status 46
Table 72: Radiofrequency Ablation Device - Product Description 46
Table 73: Imricor Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 47
Table 74: Vision MR Ablation Catheter - Product Status 47
Table 75: Vision MR Ablation Catheter - Product Description 47
Table 76: Imricor Medical Systems Inc - Ongoing Clinical Trials Overview 48

1.2 List of Figures
Figure 1: Ablation Equipments - Pipeline Products by Stage of Development 11
Figure 2: Ablation Equipments - Pipeline Products by Territory 12
Figure 3: Ablation Equipments - Pipeline Products by Regulatory Path 13
Figure 4: Ablation Equipments - Pipeline Products by Estimated Approval Date 14
Figure 5: Ablation Equipments - Ongoing Clinical Trials 15